Research Topics

J P Dutcher

Summary

Publications

  1. Fishman M, Dutcher J, Clark J, Alva A, Miletello G, Curti B, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer. 2019;7:84 pubmed publisher
    ..PROCLAIM, NCT01415167 was registered with ClinicalTrials.gov on August 11, 2011, and initiated for retrospective data collection until 2006, and prospective data collection ongoing since 2011. ..
  2. Dutcher J, De Souza P, McDermott D, Figlin R, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26:202-9 pubmed publisher
    ..Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC. ..
  3. request reprint
    Dutcher J, Lee S, Gallagher R, Makary A, Hines J, Londer H, et al. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993). Leuk Lymphoma. 2005;46:377-85 pubmed
    ..Combination therapy with other differentiating agents may be useful in this disease. ..
  4. Alva A, Daniels G, Wong M, Kaufman H, Morse M, McDermott D, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65:1533-1544 pubmed
    ..These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents. ..
  5. Clark J, Wong M, Kaufman H, Daniels G, Morse M, McDermott D, et al. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer. 2017;15:31-41.e4 pubmed publisher
    ..Patients with PD after HD IL-2 appear to benefit from follow-on TT. Patients who progressed on TT and received follow-on HD IL-2 experienced major clinical benefit. HD IL-2 therapy should be considered in eligible patients. ..
  6. Curti B, Daniels G, McDermott D, Clark J, Kaufman H, Logan T, et al. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017;5:102 pubmed publisher
    ..IrAEs resulting from IL-2 and from CPIs are qualitatively different, and likely reflect different mechanisms of action of immune activation and response. ..
  7. Blakley M, Dutcher J, Wiernik P. Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. Leuk Res. 2018;67:39-44 pubmed publisher
    ..This is the first report of familial LCH, AML, and MF in one family. The pedigree suggests a common basis for these entities, which is further suggested by the presence of anticipation in the pedigree. ..
  8. Dutcher J, Wiernik P, Varella L, Chintapatla R. Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families. Fam Cancer. 2016;15:677-87 pubmed publisher
    ..Families also appear to have an increased association. The appearance of anticipation suggests that genetic factors may be significant in this association of RCC and HM. ..